17.04.2019
The First Russian Microgen’s Pentavalent Vaccine Approval
29.03.2019
Russian Botulinum Toxin Will be Used to Treat Chronic Migraine
13.02.2019
Microgen Expands Indications for Russian Botulinum Toxin in Neurology
31.10.2018
Russian Bacteriophages are Used for Emergency Prevention of Infections
10.10.2018
Microgen Developed a Drug to Combat Immunodeficiency
04.09.2018
Microgen Developed a New Russian Avian Influenza A (H7N9) Vaccine
01.06.2018
Microgen Development Will Allow To Treat Cerebral Palsy
16.04.2018
The World's First Universal Bacteriophage Capsules are Developed to Combat Infections
25.07.2017
Russian Tick-Borne Encephalitis Vaccines Confirmed Quality at the Gene Level in Compliance with the WHO Guidelines
13.07.2017
Microgen Enhances the Tuberculosis Vaccines Production Control at the Gene Level
12.07.2017
Bacteriophages Ensured Infection Control in the Tyumen Oblast
10.07.2017
Microgen Becomes of Strategic Importance for Russia
26.04.2017
Microgen Introduces Technology to Accelerate the Quality Control of Tuberculosis Vaccines
19.09.2016
The First Russian Botulinum Toxin is Approved for Use in Neurology
05.10.2015
Perm scientists presented «Diphage» - innovational complex product to treat nosocomial infections
28.09.2015
In Moscow Microgen announced results of first year of using a unique Russian A-type botulinum toxin «Relatox®» in aesthetic medicine
21.09.2015
Seasonal vaccination against flu using new «Sovigripp» vaccine has started in Russia
17.08.2015
Microbiologists form NGO Microgen patented a novel symptom-modifying drug product which has no analogues on the Russian market.
04.08.2015
NGO Microgen implemented a unique system of quality and efficiency control of each dose of the tick-borne encephalitis vaccine
02.07.2015
Clinical trials of two new Russian-made pentavalent vaccines were stated